SCD and atherosclerosis: Supporting this hypothesis, dietary supplementation with ω-3 PUFAs has been shown to mitigate the side-effects associated with SCD1 inhibition in Ldlr−/−ApoB100/100 mice, including the acceleration of atherosclerosis, lipoprotein abnormalities, and heightened toll-like receptor 4 (TLR4) sensitivity [62].